Reporte zur Charge ULUMZ(U/O)A

Symptomtext

first dose of Moderna COVID19 vaccine 03feb2021 and is scheduled for the second dose tomorrow, 23mar2021; This spontaneous case was reported by a patient and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose of Moderna COVID19 vaccine 03feb2021 and is scheduled for the second dose tomorrow, 23mar2021) in a 66-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. ULUMZ(U/O)A) for COVID-19 vaccination. The patient's past medical history included No adverse event (No reported medical history). On 03-Feb-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose of Moderna COVID19 vaccine 03feb2021 and is scheduled for the second dose tomorrow, 23mar2021). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (first dose of Moderna COVID19 vaccine 03feb2021 and is scheduled for the second dose tomorrow, 23mar2021) had resolved. The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown. No treatment details were reported. No relevant concomitant medications were reported.; Sender's Comments: This report refers to a case of Inappropriate Schedule Of Product Administration for mRNA-1273 (Lot number: ULUMZ(U/O)A) with no associated AEs.